Guide
Retatrutide Vendors: How to Find and Verify Research Sources
Retatrutide vendors are verified on four documents, not claims. A 10 mg vial at $100 is $10.00/mg; the 20 mg at $195 drops it to $9.75/mg.
- retatrutide
- vendors
- sourcing
- coa
Verify a retatrutide vendor on four documents rather than on its copy: a lot-specific certificate of analysis naming both the testing lab and the method, a business registration you can look up in a public register, a vial-format spec whose stated mass matches that COA, and a price you can reduce to dollars per mg. No vendor holds an approved retatrutide product. The compound is a triple agonist of the GIP, GLP-1 and glucagon receptors still under evaluation in the four phase 3 TRIUMPH registrational trials, which assign over 5800 participants to weekly subcutaneous retatrutide or placebo.
What does a retatrutide vendor have to document?
Each of the four documents is falsifiable. You can check it or you cannot, and a vendor that will not produce one has answered the question anyway.
The COA is first because it is the only document tied to physical material. It has to carry a lot number that also appears on the vial label, name the analytical method behind each figure (high-performance liquid chromatography for purity, mass spectrometry for identity), and name the laboratory that ran them. A COA without a lot number describes some batch, somewhere, and cannot be matched to what ships.
The registration is second because it establishes that a legal entity exists behind the storefront. Public entity searches return a formation date and a registered agent, and checking a vendor’s business registration takes about the same time as reading the product page.
The format spec and the price are third and fourth, and they fail together. A listing that names a vial “RETA 10” without stating milligrams anywhere in the specification table cannot be priced per mg, which means it cannot be compared to anything. Research-use-only material is still material with a mass.
What does retatrutide cost per mg across the listed vial sizes?
Divide the listed price by the vial mass. The two figures below come from this retatrutide vendors listing, read on 9 September 2026; a page that quotes only a per-vial number is asking you to do this division yourself, in your head, while comparing it to another vendor’s different vial size.
| Format | Listed price (USD) | Cost per mg (price ÷ mg) | Cost to reach 20 mg (USD) |
|---|---|---|---|
| 10 mg vial | 100 | 100 ÷ 10 = 10.00 | 2 × 100 = 200 |
| 20 mg vial | 195 | 195 ÷ 20 = 9.75 | 195 |
Cost per mg for the two retatrutide vial formats carried on heezresearch.com, prices as of September 2026. Both right-hand columns are arithmetic on the two listed prices; no other source is involved.
The 20 mg format reaches the same 20 mg for $5 less, which is 5 ÷ 200 = 2.5% off the two-vial route. That is a small gap, and saying so is the point: a 2.5% per-mg advantage is not a reason to prefer a vendor whose COA you cannot check. Per-mg spreads get wide enough to matter at volume, which is where cost per mg falls at higher order tiers becomes the deciding number rather than a rounding difference.
Two per-mg figures are only comparable if they were read on the same day. Vendors revise prices without revising the page date, so write the read date next to every figure you copy.
Which numbers in vendor copy can you check against the trial record?
Listings borrow percentages from the published phase 2 obesity trial, usually without saying which dose arm or which timepoint produced them. The trial itself is specific.
| Weekly subcutaneous arm | LS mean body-weight change at 24 weeks |
|---|---|
| Placebo | −1.6% |
| Retatrutide 1 mg | −7.2% |
| Retatrutide 4 mg (combined) | −12.9% |
| Retatrutide 8 mg (combined) | −17.3% |
| Retatrutide 12 mg | −17.5% |
Primary-endpoint results from the phase 2 randomized placebo-controlled retatrutide obesity trial: 338 adults randomized, dosed once weekly for 48 weeks, primary endpoint measured as percentage change in body weight from baseline to 24 weeks.
Two arithmetic points fall straight out of that single trial. The 12 mg arm sits 17.5 − 17.3 = 0.2 percentage points from the 8 mg arm at 24 weeks, so listing copy that presents the top dose as a step change is overstating a within-trial gap of two tenths of a point. Against placebo, the 12 mg arm is 17.5 − 1.6 = 15.9 percentage points, which is the number a careful listing would quote.
The same trial also reported values at 48 weeks, and they are larger than the 24-week figures. That is why a bare percentage in a listing is uncheckable: without the arm and the timepoint, it maps to nothing in the record.
How do you tell a primary source from a reseller?
A reseller’s COA carries someone else’s letterhead, and the lot number on it will not correspond to a manufacturing record the vendor can produce. That is not disqualifying by itself. It changes what the paperwork proves: the reseller is attesting that a lot it did not make matched a spec it did not set.
Ask for the synthesis or fill date alongside the test date. When those two dates come from different documents with no lot number joining them, tracing a listing back to its source is the check that separates a distributor with real supply-chain records from a dropshipper with a PDF.
A vendor that switches manufacturers mid-catalog will show it in the COA header before it shows it anywhere else, which is one reason to save the PDF rather than the screenshot.
What should you record before you compare two retatrutide vendors?
Log six fields per listing, in this order: vial mass in mg, listed price, price ÷ mg computed by you, lot number, testing lab name, and the date you read the page. The computed per-mg figure is the only one that stays useful after a price change, because you can recompute it the next time you look. Running those six fields side by side is what comparing two vendor listings field by field amounts to in practice.
Two of the six are the fields vendors most often omit. A listing can state a purity percentage without naming the lab that measured it, and it can state a price without stating a mass outside the product title.
If the vendor names a testing lab, look the lab up before you look the vendor up. A lab with a resolvable address and a published test menu makes every COA it signed checkable; a lab name that returns nothing makes the COA a picture of a document.